anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1388878 Antibiotics A28695A and A28695B ELI LILLY & CO 4 Dec 1972 [23 Dec 1971 27 Sept 1972] 55939/72 Heading C2A The novel antibiotics A28695A and A28695B which are non-nitrogenous, acidic, white crystalline solids melting at 97 to 99 C. and 122 to 124 C. respectively and having the respective elemental compositions: C=63À31%, H=8À83%, O=28À03% and C=60À49%, H= 9À15%, O=31À32%; and molecular weights: 834 and 846, are produced by aerobically cultivating Streptomyces albus (NRRL 3883) in aqueous nutrient medium containing assimilable sources of carbon, nitrogen and inorganic salts until a substantial amount of the said antibiotics have accumulated in the culture medium. The antibiotics are extracted from the mycelium and the culture fitrate with an appropriate organic solvent, e.g. methanol or ethyl acetate for the mycelium and ethyl acetate for the filtrate, the extracts then being combined and concentrated to an oily residue which is taken up in chloroform and the solution is purified by treatment with carbon. Evaporation of the chloroform solution gives a crude mixture of the two antibiotics. These are separated and isolated as their mixed sodium/potassium salts by cromatography on a silica gel column, eluting with a benzene: ethyl acetate (4 :1) solvent, when the sodium/potassium salt of A28695A is eluted first followed by the corresponding salt of A28695B. The salts are purified by recrystallization from ether. The free acids may be prepared by treating these salts with HCl. The mixed sodium/potassium salts of A28695A and A28695B are characterized by the respective following properties: Melting points: 161 to 165 C. and 170 to 172 C.; specific rotation, [α]<SP>25</SP> D = + 14À07 and +10À1 (C=1 in methanol); and infra-red absorption spectra as shown in Fig. 1, and in Fig. 2. Both salts are white crystalline materials, insoluble in water, slightly soluble in methanol and soluble in most other organic solvents. The antibiotics A28695A and A28695B and their salts have antibacterial, antiviral, antifungal, insecticidal and anthelmintic activity. They may be used in compositions for treating plants infected with fungi or viruses, in animal feed compositions or pre-mixes therefor to increase feed efficiency, and in compositions for administration to poultry to treat or prevent avian coccidiosis.
Carefully consider the potential benefits and risks of indomethacin extended-release capsules and other treatment options before deciding to use indomethacin extended-release capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). 

Indomethacin extended-release capsules have been found effective in active stages of the following:

1\. Moderate to severe rheumatoid arthritis including acute flares of chronic disease.   
2\. Moderate to severe ankylosing spondylitis.   
3\. Moderate to severe osteoarthritis.   
4\. Acute painful shoulder (bursitis and/or tendinitis).   
Indomethacin extended-release capsules, USP are not recommended for the treatment of acute gouty arthritis.   
Indomethacin may enable the reduction of steroid dosage in patients receiving steroids for the more severe forms of rheumatoid arthritis. In such instances the steroid dosage should be reduced slowly and the patients followed very closely for any possible adverse effects.   
The use of indomethacin in conjunction with aspirin or other salicylates is not recommended. Controlled clinical studies have shown that the combined use of indomethacin and aspirin does not produce any greater therapeutic effect than the use of indomethacin alone. Furthermore, in one of these clinical studies, the incidence of gastrointestinal side effects was significantly increased with combined therapy. (See PRECAUTIONS,Drug Interactions).
Essential tremor (ET) is a prevalent neurological disorder with a largely unknown underlying biology. In this genome-wide association study meta-analysis, comprising 16,480 ET cases and 1,936,173 controls from seven datasets, we identify 12 sequence variants at 11 loci. Evaluating mRNA expression, splicing, plasma protein levels, and coding effects, we highlight seven putative causal genes at these loci, including CA3 and CPLX1. CA3 encodes Carbonic Anhydrase III and carbonic anhydrase inhibitors have been shown to decrease tremors. CPLX1, encoding Complexin-1, regulates neurotransmitter release. Through gene-set enrichment analysis, we identify a significant association with specific cell types, including dopaminergic and GABAergic neurons, as well as biological processes like Rho GTPase signaling. Genetic correlation analyses reveals a positive association between ET and Parkinson's disease, depression, and anxiety-related phenotypes. This research uncovers risk loci, enhancing our knowledge of the complex genetics of this common but poorly understood disorder, and highlights CA3 and CPLX1 as potential therapeutic targets.
To obtain cellulosic fibres containing enzymes, capable of displaying a catalytic activity in enzymatic reactions, a substituted cellulose derivative is dissolved in a water-insoluble solvent. An aqueous solution of the enzyme is then added to the solution, and the emulsion is subjected to spinning and coagulation conditions. Finally, the fibre obtained is treated with a reducing agent, in order to remove the substituent under operating conditions which do not damage the enzyme. The substituted cellulose derivative can, for example, be nitrocellulose. In this case, the reducing agent is a solution of ammonium sulphide. The said substituted cellulose derivative is dissolved in a water-insoluble solvent selected from normal-butyl acetate, dibutyl phthalate, methyl amyl ketone and ethyl amyl ketone.   The enzyme used is selected from uricase, invertase, lactase, acylase, transaminase, glucose oxidase, catalase, papain, tryptophan synthetase and penicillin amidase. This gives cellulose fibres having a permeability very much higher than that of the same fibres based on substituted cellulose.
Compositions and methods for binding to  Salmonella  bacteria are provided. The compositions comprise peptide sequences which bind to  Salmonella  bacteria with high specificity. The compositions are useful in identification, detection, and isolation of  Salmonella  bacteria. The compositions are also useful for the delivery of a wide variety of compounds to  Salmonella  bacteria or their vicinity. Such compounds include nucleotides, proteins (including, for example, toxins), liposomes, and small molecule pharmaceuticals. The compositions are also useful in identifying bacterial cell surface markers to which the compositions bind.
Locomotor and balance disorders are major limitations for subjects with hemiparesis. The Timed Up and Go (TUG) test is a complex navigational task involving oriented walking and obstacle circumvention. We hypothesized that subjects with hemiparesis adopt a cautious gait during complex locomotor tasks. The primary aim was to compare spatio-temporal gait parameters, indicators of cautious gait, between the locomotor subtasks of the TUG (Go, Turn, Return) and a Straight-line walk in people with hemiparesis. Our secondary aim was to analyze the relationships between TUG performance and balance measures, compare spatio-temporal gait parameters between fallers and non-fallers, and identify the biomechanical determinants of TUG performance. Biomechanical parameters during the TUG and Straight-line walk were analyzed using a motion capture system. A repeated measures ANOVA and two stepwise ascending multiple regressions (with performance variables and biomechanical variables) were conducted. Gait speed, step length, and % single support phase (SSP) of the 29 participants were reduced during Turn compared to Go and Return and the Straight-line walk, and step width and % double support phase were increased. TUG performance was related to several balance measures. Turn performance (R2 = 63%) and Turn trajectory deviation followed by % SSP on the paretic side and the vertical center of mass velocity during Go (R2 = 71%) determined TUG performance time. People with hemiparesis adopt a cautious gait during complex navigation at the expense of performance.
Hair or other keratinous fibre is dyed by applying an aqueous solution or cream containing at least one compound of the formula <FORM:0887579/IV (c)/1> wherein R, R1 and R2 may be the same or different and represent hydrogen atoms or methyl groups, at least one of R, R1 or R2 being a methyl group, and developing the dye by oxidation.  The solution or cream may also contain sodium chloride and a sequestering agent, such as ethylenediamine - N - bis - hydroxyethyl - N1 - diacetic acid, ethylene-diamine tetracetic acid, the trisodium salt of N-hydroxy-ethyl-ethylene-diamine triacetic acid or cyclohexane - 1,2 - diamine-N,N1-tetracetic acid, and if desired, ethyl alcohol, isopropyl alcohol, glycols or glycol esters. Oxidation may be effected with air which may be ozonised. Alternatively a solution of an oxidising agent, such as hydrogen peroxide, sodium bromate, sodium percarbonate, sodium persulphate or ammonium persulphate, at a pH above or below 7, may subsequently be applied.  To adjust the pH to below 7 an organic acid, such as lactic or monochloracetic acid, may be added, and to adjust the pH to above 7 the solution may contain ammonia or an amine.  As a further alternative, a solution of an oxidising agent containing an alkaline agent and, if desired, an antioxidant, such as a mercaptan or sulphite, may be mixed with the solution or cream containing the indole derivative immediately before use. Numerous examples are given.  Specifications 797,174 and 823,503 are referred to.
INTRODUCTION: Distinguishing paracentric inversions (PAIs) from chromosomal insertions has traditionally relied on fluorescent in situ hybridization (FISH) techniques, but recent advancements in high-throughput sequencing have enabled the use of genome sequencing for such differentiation. In this study, we present a 38-year-old male carrier of a paracentric inversion on chromosome 2q, inv (2)(q31.2q34), whose partner experienced recurrent miscarriages.
MATERIAL AND METHODS: FISH analysis confirmed the inversion, and genome sequencing was employed for detailed characterization.
RESULTS: Preimplantation genetic testing (PGT) revealed that all assessed embryos were balanced, consistent with the low risk of unbalanced offspring associated with PAIs. While PAI carriers traditionally exhibit low risk of producing unbalanced offspring, exceptions exist due to crossover events within the inversion loop. Although the sample size was limited, the findings align with existing sperm study data, supporting the rare occurrence of unbalanced progeny in PAI carriers.
CONCLUSIONS: This study highlights the possibility of characterizing PAIs using genome sequencing to enable correct reproductive counseling and PGT decisions. Detailed characterization of a PAI is crucial for understanding potential outcomes and guiding PGT strategies, as accurate knowledge of the inversion size is essential for appropriate method selection in PGT. Given the very low risk of unbalanced offspring in PAI carriers, routine PGT may not be warranted but should be considered in specific cases with a history of unbalanced progeny or recurrent miscarriages. This study contributes to our understanding of PAI segregation and its implications for reproductive outcomes.
Most gynecologic and many intra-abdominal malignancies are treated with an initial surgical procedure. There has been a dramatic increase in obesity rates in the US with more than one third of US adults being obese (Body Mass Index (BMI) of \> 30kg/m2). There is a direct link between obesity and wound complications following surgery with an increasing BMI leading to increasing rates of complications. Negative pressure wound therapy (NPWT) is a system that utilizes sub-atmospheric pressure to improve wound healing by increasing the formation of granulation tissue. NPWT has been shown to improve outcomes in both the orthopedic and cardiothoracic surgery populations. To date, there is no prospective study evaluating the application of prophylactic NPWT in laparotomy patients.

This study will be a randomized clinical trial. Patients will be enrolled at the time of consent for laparotomy for suspected gynecologic malignancy. Participants will be randomized to one of two groups: 1) Standard closure group (control arm): closure of the fascia, subcutaneous tissue and skin per the surgeon's standard method; or 2) NPWT group (study arm): closure of the fascia, subcutaneous tissue and skin per the surgeon's standard method + placement of a negative pressure wound therapy device over the closed incision for 2-3 days, with removal of the device prior to hospital discharge. The rate of wound complications for two groups will be compared.
Participants with ROS1 fusion-positive locally advanced or metastatic solid tumors will receive JYP0322 at a dose of 100 mg qd. This arm assesses safety, tolerability, and pharmacokinetics (PK) data for this dose level.
PURPOSE: To provide a body cleansing compsn. containing alcohol ethoxyglycerylsulfonate as an effective component which is less stimulant to skin and excellent in cleansing power. CONSTITUTION: The compsn. contains alcohol ethoxyglycerylsulfonate, preferably an anionic surfactant expressed by the formula as an effective component by 1 to 60 wt.%. If necessary, soap, additional anionic surfactant (such as alcohol ethcersuflate), nonionic surfactant, amphoteric surfactant, gum, polyquatarnuims may be compounded. The compsn. can be prepared into a solid soap, composite lumpy material with soap and other surfactant, surfactant lumpy material, shampoo, liquid soap, foaming soln., shower gel and the like. The obtd. agent can be used in a hard water, shows good foaming performance and can be easily processed in a normal equipment for a soap. In the formula, R is 4-20C aliphatic or mixed aliphatic group, (n) is 1-10.
Symptoms following acute overdoses with non-steroidal anti-inflammatory drugs are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and coma may occur, but are rare. Anaphylactoid reactions have been reported with therapeutic ingestion of non-steroidal anti-inflammatory drugs, and may occur following an overdose.

Patients should be managed by symptomatic and supportive care following overdose with a non-steroidal anti-inflammatory drug. There are no specific antidotes. Emesis and/or activated charcoal (60 g to 100 g in adults, 1 to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms, or following a large overdose (5 to 10 times the usual dose). Forced diuresis, alkalization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.
This is a study to evaluate biodistribution, pharmacokinetics and safety of \[18F\]THK-5351 positron emission computed tomography. Ten cognitively healthy subjects and 10 patients with Alzheimer's Disease will be enrolled. The primary outcome measures are to evaluate pharmacokinetics of \[18F\]THK-5351 Positron Emission Tomography imaging . Tracer biodistribution will be evaluated by global and regional standardized uptake value ratio of \[18F\]THK-5351 in the brain. Safety. For safety assessment, a physical examination, Electrocardiogram and vital signs will be performed at baseline and at the completion of all imaging to assess for interval change.
Myeloproliferative neoplasms are stem cell-driven cancers associated with a large burden of morbidity and mortality. Most patients present with early-stage disease, but a substantial proportion progress to myelofibrosis or secondary leukemia, advanced cancers with a poor prognosis and high symptom burden. Currently, it remains difficult to predict progression, and therapies that reliably prevent or reverse fibrosis are lacking. A major bottleneck to the discovery of disease-modifying therapies has been an incomplete understanding of the interplay between perturbed cellular and molecular states. Several cell types have individually been implicated, but a comprehensive analysis of myelofibrotic bone marrow is lacking. We therefore mapped the cross-talk between bone marrow cell types in myelofibrotic bone marrow. We found that inflammation and fibrosis are orchestrated by a "quartet" of immune and stromal cell lineages, with basophils and mast cells creating a TNF signaling hub, communicating with megakaryocytes, mesenchymal stromal cells, and proinflammatory fibroblasts. We identified the β-galactoside-binding protein galectin-1 as a biomarker of progression to myelofibrosis and poor survival in multiple patient cohorts and as a promising therapeutic target, with reduced myeloproliferation and fibrosis in vitro and in vivo and improved survival after galectin-1 inhibition. In human bone marrow organoids, TNF increased galectin-1 expression, suggesting a feedback loop wherein the proinflammatory myeloproliferative neoplasm clone creates a self-reinforcing niche, fueling progression to advanced disease. This study provides a resource for studying hematopoietic cell-niche interactions, with relevance for cancer-associated inflammation and disorders of tissue fibrosis.
Out of 12 randomized patients, 9 will receive abediterol 5 μg as dry inhalation powder orally once daily for 9 days. Patients will be provided salbutamol as rescue medication for use throughout the study. During the treatment period, all patients will be continued on their current ICSs. In addition, each patient will receive Abediterol 5.0 μg QD.
A cosmetic composition and a method for preparing the cosmetic composition are provided. The cosmetic composition includes an aqueous phase and oil phase. The aqueous phase comprises at least one water soluble ingredient including at least one non-ionic surfactant. The oil phase comprises a transformative agent, at least one thickener and at least one solvent. The transformative agent comprising at least 1% of at least one butter and at least 1% of at least one oil, the transformative agent having a butter to oil ratio of from about 2:5 to about 9:10. The cosmetic composition has a transformative texture.
eMAC is a new index based on response surface model for evaluating anesthesia state and anti-nociceptive stimulation levels. To valid it's clinical accuracy, a protocol was designed.

Patients will be allocated to receive a specific effect-site concentration of remifentanil and propofol during tonic electrical stimulation (5s, 50mA) and intubation. The concentration combinations include the electrical stimulation combination (effector chamber concentration random: remifentanil 0-3 ng/ml, propofol 3-5 ug/ml) and the intubation combination (effector chamber concentration random: remifentanil 3-5 ng/ml, propofol 3-5 ug/ml). All combinations were decided before operation. Every combination had a 5 min equilibration period, and the vital signs (Heart Rate, Blood pressure, any body movement) and BIS, eMAC will be recorded before and after the electrical stimulation and intubation. After this period, patients will be randomly allocated to receive an intravenous anesthesia or intravenous combined anesthesia, and regular anesthesia is executed. This study only records vital signs and BIS, eMAC during maintenance period of perioperative.
Reticulocalbin 1 (RCN1) is a calcium-binding protein involved in the regulation of calcium homeostasis in the endoplasmic reticulum. The aim of this study was to explore the clinical value and biological role of RCN1 in esophageal squamous cell carcinoma (ESCC). In addition, we investigated the effect of RCN1 on the polarization of tumor-associated macrophages (TAMs). The GSE53625 dataset from the Gene Expression Omnibus database was used to analyze the expression of RCN1 mRNA and its relationship with clinical value and immune cell infiltration. Immunohistochemistry was used to validate the expression of RCN1 and its correlation with clinicopathological characteristics. Subsequently, transwell and cell scratch assays were conducted to evaluate the migration and invasion abilities of ESCC cells. The expression levels of epithelial-mesenchymal transition (EMT)-related proteins were evaluated by western blot, while apoptosis was detected by flow cytometry and western blot. Additionally, qRT‒PCR was utilized to evaluate the role of RCN1 in macrophage polarization. RCN1 was significantly upregulated in ESCC tissues and was closely associated with lymphatic metastasis and a poor prognosis, and was an independent prognostic factor for ESCC in patients. Knockdown of RCN1 significantly inhibited the migration, invasion, and EMT of ESCC cells, and promoted cell apoptosis. In addition, RCN1 downregulation inhibited M2 polarization. RCN1 is upregulated in ESCC patients and is negatively correlated with patient prognosis. Knocking down RCN1 inhibits ESCC progression and M2 polarization. RCN1 can serve as a potential diagnostic and prognostic indicator for ESCC, and targeting RCN1 is a very promising therapeutic strategy.
Subjects in the ANA001 treatment arm will receive 1,000 mg (4 capsules; 250 mg each) by mouth twice per day for 7 consecutive days with a meal. If the participant requires mechanical ventilation over the course of the study, ANA001 may be administered via nasogastric (NG), percutaneous endoscopic gastrostomy (PEG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.
Pulmonary rehabilitation is a key element in the management of individuals with chronic respiratory disease. A properly followed supervised physical training program in sarcoidosis is safe and has no absolute contraindications. Fatigue may be associated with different causes in sarcoidosis. Individualized rehabilitation practices can improve the symptoms of patients with sarcoidosis. There is no study in the literature investigating the effectiveness of one-legged exercises that reduce peripheral muscle use in patients with sarcoidosis. In our study, these two exercise methods will be compared by applying one-legged exercise training and two-legged exercise training. 26 patients will be randomly divided into 2 groups (n1=n2=13). While one group will receive one-legged cycling ergometer training, the other group will receive two-legged cycling ergometer training. After 8 weeks of exercise training, patients will be evaluated with, Pulmonary Function Test, Six-Minute Walk Test, Endurance Shuttle Walk test, Fatigue Assessment Scale, Multidimensional Fatigue Inventory, Blood Lactate Level (with lactate device), Medical Research Council Dyspnea Scale, Handheld dynamometer, St. George's Respiratory Questionnaire. The effect of one-legged exercise training on exercise capacity and fatigue in sarcoidosis patients will be examined. The primary aim of our study is to compare the effects of one-legged exercise training, which is a current exercise approach, and two-legged exercise training on exercise capacity and fatigue in patients with sarcoidosis. The secondary aim is to examine the effect of this exercise training on peripheral muscle strength and quality of life parameters. The completion of the study will contribute to the determination of the content of the exercise programs to be applied in sarcoidosis patients and will reveal the effectiveness of one-legged exercise training, which is a current exercise method, in sarcoidosis patients.
The initial pressure support ventilation setting was a driving pressure of 7 cm H2O, PEEP of 5 cm H2O, and safety backup ventilation of 12 breaths/min (safety backup ventilation setting, VT, 8 ml/kg of predicted body weight; and PEEP, 5 cm H2O). The flow trigger and end of breath were set at 2 l/min and 30% of peak flow, respectively.